Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

Johann S de BonoUgo De GiorgiDaniel Nava RodriguesChristophe MassardSergio BracardaAlbert FontJose Angel Arranz ArijaKent C ShihGeorge Daniel RadavoiNa XuWai Y ChanHan MaSteven GendreauRuth RiisnaesPremal H PatelDaniel J MaslyarViorel Jinga

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

In mCRPC, combined blockade with abiraterone and ipatasertib showed superior antitumor activity to abiraterone alone, especially in patients with PTEN-loss tumors.See related commentary by Zhang et al., p. 901.

Keyphrases

phase ii study
open label
prostate cancer
cell proliferation
placebo controlled
pi k akt
double blind
signaling pathway
phase iii
locally advanced
radical prostatectomy
phase ii
clinical trial
study protocol
drug induced